EU Agency Demands Cancer Drug Recall Due To Sterility Risks

Law360, Chicago (August 24, 2012, 3:27 PM ET) -- The European Medicines Agency said Friday that the cancer medicine DepoCyte should be recalled from all European Union countries where alternative treatments are available, after an inspection at Pacira Pharmaceuticals Inc.'s manufacturing site for the drug revealed potential sterility issues.

The EU agency's Committee for Medicinal Products for Human Use recommended the recall as a precautionary measure, according to the EMA, which said there was currently no evidence of any microbial contamination of the medicine on the market or risk to patients.

The recall recommendation follows...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required